Enduron and Dermographism - a phase IV clinical study of FDA data
Summary:
We study 151 people who take Enduron (methyclothiazide) or have Dermographism. No report of Dermographism is found in people who take Enduron.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Enduron?
Enduron has active ingredients of methyclothiazide. eHealthMe is studying from 66 Enduron users. Check the latest studies of Enduron.
What is Dermographism?
Dermographism (skin writing- is a skin disorder) is found to be associated with 24 drugs and 45 conditions by eHealthMe. Check the latest studies of Dermographism.
No report is found.
Do you take Enduron and have Dermographism?
- Check whether Dermographism is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Enduron:
- Enduron (66 reports)
Dermographism treatments and more:
- Dermographism (85 reports)
How severe was Dermographism and when was it recovered:
Expand to all the drugs that have ingredients of methyclothiazide:
Browse all side effects of Enduron:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Dermographism:
Browse all the conditions that are associated with Dermographism:
How the study uses the data?
The study uses data from the FDA. It is based on methyclothiazide (the active ingredients of Enduron) and Enduron (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of Aminophyllin and Oxazepam - 10 seconds ago
- Red Blood Cell Sedimentation Rate Increased and drugs of ingredients of cetirizine hydrochloride - 20 seconds ago
- Drug interactions of Losartan and Soriatane - 21 seconds ago
- Could Lupron Depot cause Hiatal Hernia? - 25 seconds ago
- Could Acetylsalicylic Acid cause Ulcerative Colitis? - 29 seconds ago
- Drug interactions of Mepron and Hydrocortisone - 37 seconds ago
- Blood Iron Decreased and drugs of ingredients of simvastatin - 52 seconds ago
- Drug interactions of Profen and Dolutegravir - 55 seconds ago
- Rebif and Asthenia for Men aged 30-39 - a minute ago
- Rebif and Muscle Fatigue for Men aged 30-39 - a minute ago